SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is actively discussed following its submission of a consolidated application for deep-sea polymetallic nodule mining to NOAA, a process now streamlined by updated US regulations. The community is highly bullish, interpreting this as a critical step towards commercialization and a national security imperative to secure vital minerals, with many anticipating rapid permit approval and significant share price upside. Talk of a potential short squeeze is also prevalent, as investors believe government support solidifies TMC's position as a key player in securing essential resources.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is generating significant buzz following news of a substantial government investment from the U.S., driving community excitement around a potentially much higher implied valuation and short squeeze opportunities. Further discussions highlight French government backing for a new rare earth facility in Europe, underscoring USAR's expanding role in securing critical mineral supply chains and reducing reliance on foreign sources.

Zoracles

Zoracles ($ZORA) is trending as the crypto community anticipates a significant market reversal and "ALT token coin season," driven by upcoming catalysts like the "Clarity Act," potential FED rate cuts, and government actions influencing broader market liquidity. Many investors are "loading up" and expressing strong conviction in its long-term growth, despite some recent stagnant price action. The token is closely watched for its correlation with Bitcoin's movements and its potential within the creator economy on Coinbase's Base app.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as intense public debate surrounds a recent controversial shooting involving federal agents in Minneapolis. This incident has sparked highly polarized discussions across social media regarding government actions, constitutional rights, and broader political tensions, significantly influencing sentiment around this politically associated company.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility driven by global market uncertainty, including US political gridlock potentially leading to a government shutdown and new tariff threats. The community remains fiercely divided, with many anticipating further declines while a persistent bullish contingent views current price points as key accumulation zones. This tension is further amplified by ongoing discussions regarding the role of institutions and the asset's performance against traditional safe havens.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

The Vanguard Total Stock Market ETF is a focal point for market sentiment, as investors closely monitor how evolving government policy and trade dynamics influence the broader economy. Community discussions reflect a blend of anxiety over sustained economic pressures like inflation and job market shifts, alongside debates about indexing's enduring value amid sector-specific growth trends. This comprehensive fund remains a key indicator of the overall market's reaction to macro-level developments.

BYD Co., Ltd. engages in the research, development, manufacture, and sale of rechargeable batteries and photovoltaic business. It operates through the following segments: Rechargeable Batteries and Photovoltaic Products, Mobile Handset Components, Assembly Service and Other Products, and Automobiles and Related Products and Other Products. The Rechargeable Batteries and Photovoltaic Products segment is involved in the manufacture and sale of lithium-ion batteries and nickel batteries, photovoltaic products, and iron batteries products for mobile phones, electric tools, and other portable electronic instruments, photovoltaic products, energy storage products, and electric vehicles. The Mobile Handset Components, Assembly Service and Other Products segment focuses on the sale of mobile handset components such as housings, electronic components, assembly services, and medical protection products. The Automobiles and Related Products and Other Products segment consists of automobiles and auto-related moulds and components and automobile leasing and after sales services, rail transport related business, and medical protection products. The company was founded by Chuan Fu Wang on February 10, 1995 and is headquartered in Shenzhen, China.

BYD Co - Ordinary Shares - Class H

BYD Co

BYD Co is trending amid impressive Q4 earnings, strong Q1 guidance, and significant global sales growth that continues to outpace rivals, particularly in Europe. The company's aggressive expansion and innovative fast-charging technology are key talking points, fueling community discussion about its increasing dominance in the competitive EV market. Investors are closely watching BYD's strategic moves as it solidifies its position as a leading global electric vehicle manufacturer.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is trending as the market anticipates a Supreme Court tariff ruling expected to bolster its U.S.-manufactured, China-independent solar panels against imports, a critical advantage amidst rising global energy demand. Community discussions highlight FSLR's unique cadmium telluride technology and domestic supply chain as key assets for powering the rapidly expanding AI data center sector. Recent analyst upgrades and a robust earnings outlook, despite some volatility, are reinforcing its position as a favored clean energy play.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

iShares Ethereum Trust ETF (ETHA) is a major focus as institutional adoption of Ethereum intensifies for real-world asset tokenization and network upgrades like Fusaka approach. The community is actively debating Ethereum's potential to significantly outperform Bitcoin, with many viewing current price levels as key accumulation opportunities ahead of anticipated catalysts and potential ETF staking developments.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is trending as investors prioritize robust inflation protection, driven by anticipation of higher inflation figures and ongoing discussions about elevated long-term interest rates. The community widely views this ETF as a reliable hedge, frequently discussing its attractive dividend yield and recent institutional accumulation as strong points. In a challenging bond market, many see VTIP as a strategic choice for stable income and preserving capital against persistent inflation concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 Earnings Forecast for AXSM Issued By HC Wainwright

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Axsome Therapeutics in a research note issued on...

Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

HC Wainwright Has Bullish Estimate for AXSM FY2026 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Axsome Therapeutics in a research report issued on...

Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade

Axsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week High After Analyst Upgrade...

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $260.00 at HC Wainwright

HC Wainwright raised their price target on shares of Axsome Therapeutics from $200.00 to $260.00 and gave the company a "buy" rating in a research note on Tuesday...

Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts

<ul class="summary-bullets"><li>Piper said it met with Axsome’s senior management recently, and gained more insights into commercial dynamics surrounding Auvelity in agitation associated with Alzheimer's disease.</li><li>Auvelity is already approved by the U.S. Food and Drug Administration for treating major depressive disorder.</li><li>For the full year 2025, the company expects $638.5 million in total product revenue, including &nbsp;$507.1 million from Auvelity.</li></ul><p>Shares of Axsome Therapeutics (AXSM) closed 2% higher on Friday after Piper Sandler hiked its price target to $223.</p><p>The firm kept an ‘Overweight’ rating on the shares and raised the price target to $223 from $148, as per TheFly. The new price target represents a potential upside of about 26% from the stock’s closing price on Friday.</p><h2 class="st-heading-2">Piper Sees Upsides</h2><p>Piper said it met with Axsome’s senior management recently, and gained more insights into commercial dynamics surrounding Auvelity in agitation associated with Alzheimer's disease.</p><p>Auvelity is already approved by the U.S. Food and Drug Administration (FDA) for treating major depressive disorder. Piper believes that a label expansion for the drug to include agitation associated with Alzheimer's is “highly likely.” The company submitted an application for the same in late December and the FDA is now expected to decide on the application by April 30, 2026.</p><h2 class="st-heading-2">Preliminary Revenue Numbers</h2><p>Earlier this week, Axsome said that it expects total product revenue of $196 million for the fourth quarter, marking a growth of 65% year-over-year. For the full year 2025, the company expects $638.5 million in total product revenue, including &nbsp;$507.1 million from Auvelity. &nbsp;This exceeds an analyst estimate of total revenue of $619.75 million for the year, as per data from Fiscal AI.</p><p>Other FDA-approved treatments from Axsome cater to excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine. The company is also developing new drugs to address a range of serious neurological and psychiatric conditions.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around AXSM stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has nearly doubled its value over the past 12 months. &nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bntx-shares-rise-on-goldman-sachs-upgrade-optimism-for-cancer-portfolio/cmUmPUSR4Bv">BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism

Piper Sandler kept an ‘Overweight’ rating on Axsome Therapeutics’ shares, and raised the price target to $223 from $148.

Equity

Piper Sandler kept an ‘Overweight’ rating on Axsome Therapeutics’ shares, and raised the price target to $223 from $148.


Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia

AXSM doses the first patient in the phase III FORWARD study testing AXS-14 for fibromyalgia.

Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65%

(RTTNews) - Axsome Therapeutics, Inc. (AXSM) said, based on preliminary financial information, Axsome expects total product revenue to be approximately $196.0 million for the fourth quarter...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AXSM News

AXSMAxsome Therapeutics Inc